Nuwellis
Eden Prairie, US · 3 known investors
Nuwellis is a commercial-stage medical device company that makes the Aquadex SmartFlow ultrafiltration system for cardiorenal fluid management. Its technology is used by clinicians to treat fluid overload in cardiac, ICU, pediatric, and kidney-failure patients, including cases of heart failure and acute kidney injury.
Founders & leadership
NP
Neil P. AyotteExecutive
RS
Rob ScottExecutive
NJ
Nestor Jaramillo, Jr.Executive
BB
Brian BrownExecutive
DA
David A. RosaExecutive
CD
Claudia DraytonExecutive
DJ
Debra J. KridnerExecutive
MW
Molly WadeExecutive
KO
Kimberly OlesonExecutive
DO
Donal O'DwyerNamed on SEC filing
DK
Debra KridnerNamed on SEC filing
KB
Kevin BassettNamed on SEC filing
Investors · 3
Reported raises · per SEC filings
Form D private placements$22.3M disclosed across 13 of 16 rounds · 2012–2024
▶$3.8MraisedNov 2024 · 9 investors · Other Health CareRule 506(b)
▶$3.8MraisedNov 2024 · 9 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Archelle Georgiou, M.D.Director
- Mike McCormickDirector
- Maria Rosa Costanzo, M.D.Director
- Nestor Jaramillo, Jr.Executive Officer, Director
- John L. ErbDirector
- Neil P. AyotteExecutive Officer
- Gregory WallerDirector
- Rob ScottExecutive Officer
- Dave Kendrick McDonaldDirector
- Offering amount
- $3.8M
- Amount sold
- $3.8M
- Sales commissions
- $382.9K
- Placement agents
- Ladenburg Thalmann & Co. Inc.
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶Undisclosed amountofferedSep 2024 · 6 investors · Other Health CareRule 506(b)
▶Undisclosed amountofferedSep 2024 · 6 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Neil P. AyotteExecutive Officer
- Nestor Jaramillo, Jr.Executive Officer, Director
- Rob ScottExecutive Officer
- Dave Kendrick McDonaldDirector
- Archelle Georgiou, M.D.Director
- Mike McCormickDirector
- John L. ErbDirector
- Maria Rosa Costanzo, M.D.Director
- Gregory WallerDirector
- Sales commissions
- $71.3K
- Placement agents
- Ladenburg Thalmann & Co. Inc.
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶Undisclosed amountofferedAug 2024 · 7 investors · Other Health CareRule 506(b)
▶Undisclosed amountofferedAug 2024 · 7 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Mike McCormickDirector
- Gregory WallerDirector
- Neil P. AyotteExecutive Officer
- Archelle Georgiou, M.D.Director
- Maria Rosa Costanzo, M.D.Director
- John L. ErbDirector
- Rob ScottExecutive Officer
- Nestor Jaramillo, Jr.Executive Officer, Director
- Dave Kendrick McDonaldDirector
- Sales commissions
- $139.3K
- Placement agents
- Roth Capital Partners, LLC
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶Undisclosed amountofferedJun 2023 · 1 investors · BiotechnologyRule 506(b)
▶Undisclosed amountofferedJun 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John L. ErbDirector
- Michael Kendrick McCormickDirector
- Nestor JaramilloExecutive Officer, Director
- Gregory WallerDirector
- Lynn Larson BlakeExecutive Officer
- Jon SalvesonDirector
- Maria Rosa CostanzoDirector
- Neil P. AyotteExecutive Officer
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.7MraisedMay 2020 · 4 investors · BiotechnologyRule 506(b)
▶$1.7MraisedMay 2020 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John L. ErbExecutive Officer, Director
- Warren S. WatsonDirector
- Claudia DraytonExecutive Officer
- Maria Rosa CostanzoDirector
- Steve BrandtDirector
- Jon SalvesonDirector
- Gregory WallerDirector
- Offering amount
- $1.7M
- Amount sold
- $1.7M
- Sales commissions
- $136K
- Placement agents
- Ladenburg Thalmann & Co. Inc.
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.2MraisedApr 2020 · 4 investors · BiotechnologyRule 506(b)
▶$2.2MraisedApr 2020 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Maria Rosa CostanzoDirector
- John L. ErbExecutive Officer, Director
- Warren S. WatsonDirector
- Gregory WallerDirector
- Jon SalvesonDirector
- Steve BrandtDirector
- Claudia DraytonExecutive Officer
- Offering amount
- $2.2M
- Amount sold
- $2.2M
- Sales commissions
- $178.1K
- Placement agents
- Ladenburg Thalmann & Co. Inc.
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.2MraisedMar 2020 · 4 investors · BiotechnologyRule 506(b)
▶$1.2MraisedMar 2020 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gregory WallerDirector
- Jon SalvesonDirector
- Maria Rosa CostanzoDirector
- Steve BrandtDirector
- Claudia DraytonExecutive Officer
- John L. ErbExecutive Officer, Director
- Warren S. WatsonDirector
- Offering amount
- $1.2M
- Amount sold
- $1.2M
- Sales commissions
- $99.9K
- Placement agents
- Ladenburg Thalmann & Co. Inc.
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.4MraisedNov 2019 · 3 investors · BiotechnologyRule 506(b)
▶$1.4MraisedNov 2019 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jon SalvesonDirector
- Gregory WallerDirector
- Warren S. WatsonDirector
- Steve BrandtDirector
- Maria Rosa CostanzoDirector
- John L. ErbExecutive Officer, Director
- Claudia DraytonExecutive Officer
- Offering amount
- $1.4M
- Amount sold
- $1.4M
- Sales commissions
- $109.2K
- Placement agents
- Ladenburg Thalmann & Co. Inc.
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Nuwellis do?
- Nuwellis is a commercial-stage medical device company that makes the Aquadex SmartFlow ultrafiltration system for cardiorenal fluid management. Its technology is used by clinicians to treat fluid overload in cardiac, ICU, pediatric, and kidney-failure patients, including cases of heart failure and acute kidney injury.
- Who are Nuwellis's investors?
- Nuwellis's investors include Ascension Ventures, Kaiser Permanente Ventures, SV Health Investors.
- How much funding has Nuwellis raised?
- Nuwellis has disclosed $22.3M raised across 13 of its 16 known rounds.
- Where is Nuwellis headquartered?
- Nuwellis is headquartered in Eden Prairie, US.